CN116836872B - 一种枯草芽孢杆菌多糖类α-淀粉酶抑制剂及其应用 - Google Patents
一种枯草芽孢杆菌多糖类α-淀粉酶抑制剂及其应用 Download PDFInfo
- Publication number
- CN116836872B CN116836872B CN202310830580.6A CN202310830580A CN116836872B CN 116836872 B CN116836872 B CN 116836872B CN 202310830580 A CN202310830580 A CN 202310830580A CN 116836872 B CN116836872 B CN 116836872B
- Authority
- CN
- China
- Prior art keywords
- alpha
- bacillus subtilis
- amylase inhibitor
- stb22
- amylase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 37
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 37
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 37
- 244000063299 Bacillus subtilis Species 0.000 title claims abstract description 35
- 235000014469 Bacillus subtilis Nutrition 0.000 title claims abstract description 35
- 239000003392 amylase inhibitor Substances 0.000 title claims abstract description 35
- 101710171801 Alpha-amylase inhibitor Proteins 0.000 title claims abstract description 27
- 238000000855 fermentation Methods 0.000 claims abstract description 32
- 230000004151 fermentation Effects 0.000 claims abstract description 31
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 17
- 239000006228 supernatant Substances 0.000 claims abstract description 11
- 238000009629 microbiological culture Methods 0.000 claims abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 19
- 230000000813 microbial effect Effects 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 5
- 229930182830 galactose Natural products 0.000 claims description 5
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 239000003472 antidiabetic agent Substances 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 26
- 210000004369 blood Anatomy 0.000 abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 17
- 102000004190 Enzymes Human genes 0.000 abstract description 14
- 108090000790 Enzymes Proteins 0.000 abstract description 14
- 241000699670 Mus sp. Species 0.000 abstract description 14
- 229940088598 enzyme Drugs 0.000 abstract description 14
- 230000000291 postprandial effect Effects 0.000 abstract description 10
- 238000009835 boiling Methods 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 7
- 102000001746 Pancreatic alpha-Amylases Human genes 0.000 abstract description 6
- 108010029785 Pancreatic alpha-Amylases Proteins 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 abstract description 5
- 229960002632 acarbose Drugs 0.000 abstract description 5
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 abstract description 5
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 4
- 208000008589 Obesity Diseases 0.000 abstract description 3
- 238000004108 freeze drying Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 244000005700 microbiome Species 0.000 abstract description 3
- 235000020824 obesity Nutrition 0.000 abstract description 3
- 239000013641 positive control Substances 0.000 abstract description 3
- 230000001376 precipitating effect Effects 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000013049 sediment Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 description 20
- 229920002472 Starch Polymers 0.000 description 18
- 239000008107 starch Substances 0.000 description 18
- 235000019698 starch Nutrition 0.000 description 18
- 239000000243 solution Substances 0.000 description 14
- 102000004139 alpha-Amylases Human genes 0.000 description 10
- 108090000637 alpha-Amylases Proteins 0.000 description 10
- 229940024171 alpha-amylase Drugs 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 5
- 230000009849 deactivation Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000019621 digestibility Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 229920002444 Exopolysaccharide Polymers 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000132152 Polymyxa Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000014101 glucose homeostasis Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000179039 Paenibacillus Species 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- FZNCGRZWXLXZSZ-CIQUZCHMSA-N Voglibose Chemical compound OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O FZNCGRZWXLXZSZ-CIQUZCHMSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- OHVGNSMTLSKTGN-BTVCFUMJSA-N [C].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [C].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O OHVGNSMTLSKTGN-BTVCFUMJSA-N 0.000 description 1
- AQFKTWYDGPSEBT-UHFFFAOYSA-N acetic acid 2-hydroxyacetonitrile Chemical compound C(C)(=O)O.C(CO)#N AQFKTWYDGPSEBT-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000021332 kidney beans Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000000110 microvilli Anatomy 0.000 description 1
- 229960001110 miglitol Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229960001729 voglibose Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/07—Bacillus
- C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明公开了一种枯草芽孢杆菌多糖类α‑淀粉酶抑制剂及其应用,属于微生物技术领域。该α‑淀粉酶抑制剂生产菌株保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCCNo.27209。本发明首先将菌株进行发酵,使其发酵液中积累一定量的α‑淀粉酶抑制剂;然后进行煮沸灭酶,去除蛋白和细胞沉淀,得到澄清上清液;进一步用无水乙醇沉淀,冷冻干燥后即得α‑淀粉酶抑制剂。该α‑淀粉酶抑制剂能强烈抑制猪胰腺α‑淀粉酶,且体外抑制效果强于阳性对照阿卡波糖,同时能明显降低小鼠的餐后血糖水平,可用于制备治疗和预防糖尿病、肥胖症的药物或功能性食品。
Description
技术领域
本发明涉及一种枯草芽孢杆菌多糖类α-淀粉酶抑制剂及其应用,属于微生物技术领域。
背景技术
淀粉作为人类膳食的重要组成和能量的主要来源,其消化性与人体健康密切相关。加工食品中绝大部分淀粉在进入人体后快速降解成葡萄糖,是引起餐后血糖上升的最主要因素。血糖稳态是维持生命正常运转的基础,而餐后血糖的剧烈波动极大增加了机体调节血糖稳态的压力,不利于机体健康,长此以往,甚至会导致糖代谢紊乱,诱发一系列代谢类疾病,如肥胖、糖尿病和心血管疾病等。降低淀粉消化性能够减弱餐后血糖负荷,有助于维持血糖稳态和机体正常运转,对于非胰岛素依赖型糖尿病和心血管疾病也具有预防和辅助治疗作用。
淀粉进入消化道后,依次经唾液α-淀粉酶、胰腺α-淀粉酶和小肠刷状缘α-葡萄糖苷酶降解,抑制这些淀粉消化酶活性是降低淀粉消化性、维持餐后血糖平衡的重要手段之一。目前常见的淀粉消化酶抑制剂以α-葡萄糖苷酶抑制剂为主,如阿卡波糖、米格列醇和伏格列波糖等。然而这些抑制剂主要作为治疗糖尿病的临床药物使用,不能满足普通人群对调控淀粉消化性的日常需求。同时,α-葡萄糖苷酶抑制剂用于减缓寡糖的降解,但寡糖在肠道中将进行厌氧发酵,从而导致胀气、腹痛和腹泻等副作用。因此,选择性抑制淀粉消化金字塔顶端的α-淀粉酶,是有效控制淀粉降解、调节血糖水平的手段。
天然存在的α-淀粉酶抑制剂从结构上可分为蛋白质、多肽、多糖及多酚类等。自20世纪70年代开始,α-淀粉酶抑制剂的研究得到了广泛的关注。目前,已从禾本科和豆科植物的种子果实中提取分离得到了蛋白类α-淀粉酶抑制剂,特别是从白芸豆中提取的α-淀粉酶抑制剂,能特异性地水解人体口腔和肠道内α-淀粉酶,国内外已将其应用为商业化的减肥保健食品。蛋白质和多肽类的α-淀粉酶抑制剂虽然对α-淀粉酶的抑制作用强,但对酸、碱或高温环境敏感。多酚类物质由于含有大量的酚羟基,导致其对α-淀粉酶的特异性较弱,也能较强地抑制体内的胃蛋白酶、胰蛋白酶和胰脂肪酶等。而多糖类α-淀粉酶抑制剂对酸碱、温度和胃肠道环境的稳定性较强,安全无毒,可作为天然的降糖产品。大多数研究已报道了植物多糖对α-淀粉酶的抑制作用,如食用菌多糖、秋葵多糖、淮山多糖、黄芪多糖等。相对于植物多糖,微生物多糖具有提取工艺简单、生产周期短、不受季节和地域限制等优点,具有较强的市场竞争力和广阔的发展前景。目前,日本学者报道了一株枯草芽孢杆菌AK(保藏编号:FERM P-18291),其发酵代谢物可以增强免疫力、抗血栓、改善db/db小鼠胰岛素抵抗以及降低血糖。该菌株16s rRNA序列与多粘芽孢杆菌(Paniebacilluspolymyxa)同源性较高,属于类芽孢杆菌属,与典型的芽孢杆菌菌种枯草芽孢杆菌(即芽孢杆菌属)亲缘关系较远。此外,该报道的发酵代谢物成分复杂,无法判断发挥降血糖功能的成分种类,也无法确定所述发酵代谢物降低血糖的原理,更没有证据证明所述发酵代谢物对于普通人群餐后血糖的调控作用。
微生物多糖安全稳定、适用于工业生产,是一种极具潜力的降血糖物质,但是尚无维持普通人群血糖稳定的微生物多糖产品。
发明内容
针对现有产品和技术存在的问题,本发明提供了一种枯草芽孢杆菌胞外多糖类α-淀粉酶抑制剂的制备方法及其应用。
本发明的第一个目的是提供一种产胞外多糖类α-淀粉酶抑制剂的枯草芽孢杆菌(Bacillus subtilis)STB22,已于2023年4月27日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.27209。
本发明的第二个目的是提供含所述枯草芽孢杆菌STB22的微生物制剂。
在一种实施方式中,所述微生物制剂中含枯草芽孢杆菌STB22活菌数≥107CFU/mL。
在一种实施方式中,所述微生物制剂还含有保护剂;所述保护剂包括但不限于甘油。
本发明的第三个目的是提供一种制备所述α-淀粉酶抑制剂的方法,所述方法包括以下步骤:
(1)发酵:于培养基中培养权利要求1所述的能产生α-淀粉酶抑制剂的生产菌株,使其发酵液中积累一定量的α-淀粉酶抑制剂;
(2)灭酶:将步骤(1)的发酵上清液于沸水中煮沸20-30min灭酶,冷却至室温。
(3)去除蛋白和细胞沉淀:向步骤(2)灭酶冷却后的溶液中加有机试剂去除蛋白,8000-10000r/min离心10-20min,除去细胞和蛋白沉淀,得到澄清上清液。
(4)乙醇沉淀:向步骤(3)的上清液中加入三倍体积的无水乙醇,4℃过夜沉淀,8000-10000r/min离心10-20min,得到沉淀。
(5)干燥:将步骤(4)的沉淀进行冷冻干燥或喷雾干燥,即得粉末状的α-淀粉酶抑制剂产品。
在一种实施方式中,所述(1)中枯草芽孢杆菌可以利用单一或复合碳源,如:葡萄糖、麦芽糖、果糖、甘露糖、半乳糖、海藻糖、乳糖、淀粉、糊精等,多种有机或无机氮源,如牛肉膏、蛋白胨、酵母粉、尿素、玉米浆、硝酸盐、铵盐等;同时加入磷酸盐、硫酸盐、乙酸钠、柠檬酸盐等无机盐和吐温后制成液体培养基进行发酵。按4-10%接种量加入活化培养菌株,于30-37℃通气培养18-24h。
在一种实施方式中,所述(3)去除蛋白的方法为:向灭酶冷却后的溶液中加入15-17%(v/v)的85%三氯乙酸,或将灭酶后的溶液进行减压蒸发浓缩后利用Sevage法去除蛋白。
本发明的第四个目的是提供所述的枯草芽孢杆菌STB22,或所述的微生物制剂,或所述的α-淀粉酶抑制剂在制备降血糖药品中的应用。
本发明的第五个目的是提供所述的枯草芽孢杆菌STB22,或所述的微生物制剂,或所述的α-淀粉酶抑制剂在制备维持血糖健康水平的保健品中的应用。
有益效果:本发明利用枯草芽孢杆菌STB22进行发酵生产胞外多糖,作为α-淀粉酶抑制剂,所得胞外多糖的得率达到706mg/L,其中总糖含量65%,蛋白质含量7.09%。所得胞外多糖具有良好的α-淀粉酶抑制活性,能在体外有效抑制猪胰腺α-淀粉酶(IC50:0.162mg/mL),且抑制能力强于市售阳性对照阿卡波糖(IC50:0.736mg/mL);同时体内实验结果显示,摄入1g/kg体重的可溶性淀粉之后,小鼠的血糖浓度在餐后15min达到峰值(15.2mmol/L),随后缓慢降低;摄入400mg/kg体重的多糖,小鼠的血糖浓度在餐后30min达到峰值(12.9mmol/L),相比于空白对照的小鼠,其峰值血糖降低15.0%(p<0.05),餐后血糖应答的曲线下方面积(AUC)降低了19.1%,表明该抑制剂能显著降低餐后高血糖,可有效地预防和管理糖尿病、肥胖病,具有良好的开发和应用前景。
生物材料保藏
一株枯草芽孢杆菌(Bacillus subtilis)STB22,分类学命名为Bacillussubtilis,已于2023年4月27日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.27209,保藏地址为北京市朝阳区北辰西路1号院3号。
附图说明
图1:阿卡波糖对猪胰腺α-淀粉酶的抑制曲线。
图2:枯草芽孢杆菌胞外多糖类α-淀粉酶抑制剂对猪胰腺α-淀粉酶的抑制曲线。
图3:枯草芽孢杆菌胞外多糖类α-淀粉酶抑制剂的分子量分布图。
图4:枯草芽孢杆菌胞外多糖类α-淀粉酶抑制剂的单糖组成。
图5:枯草芽孢杆菌胞外多糖类α-淀粉酶抑制剂对小鼠餐后血糖曲线(A)及AUC(B)的影响。
具体实施方式
通过以下具体实施例对本发明的技术方案作进一步说明,但本发明所保护的范围的不局限于此。
α-淀粉酶抑制率的测定方法:
以0.2M PBS(pH 6.9)配制1%可溶性淀粉溶液作为底物,取0.180mL猪胰腺α-淀粉酶(Sigma,货号:A3176)溶液于10mL试管中,加入0.020mL待测样品,混合均匀后置于37℃水浴锅孵育10min,取0.1mL混合溶液加入到1%可溶性淀粉中,反应10min后加入1.0mL DNS显色剂,沸水中反应5min后取出,立即冰浴冷却,加入2mL水混匀后于540nm下测定吸光度值。
按下式计算样品对α-淀粉酶的抑制率:
式中:
A1:空白管(加酶液,不加样品)的吸光度值;
A2:空白对照管(不加酶液和样品)的吸光度值;
A3:抑制管(加酶液和样品)的吸光度值;
A4:抑制对照管(加样品,不加酶液)的吸光度值。
IC50的定义:半抑制浓度,即当酶活被抑制为50%时的抑制剂的浓度。
分子量测定方法:
采用高效凝胶过滤色谱法(HPGFC)测定样品的分子量。称取2mg样品和不同分子量的葡聚糖标准品,制备成2mg/mL的溶液,然后向Agilent 1100高效液相色谱仪进样10μL,以超纯水为流动相(柱温:30℃,流速:1mL/min),并在示差折光检测器下检测,然后绘制标准曲线。根据样品的保留时间,计算出样品的分子量。
单糖组成测定方法:
将5mg多糖样品在1mL三氟乙酸(TFA,2mol/L)中110℃水解2h。除尽TFA后,采用用糖腈乙酸酯衍生化法对其进行衍生化:分别加入盐酸羟胺5mg和吡啶0.25mL,并于90℃条件下反应30min。再加入乙酸酐0.25mL反应30min。单糖标准品(葡萄糖、阿拉伯糖、鼠李糖、甘露糖、木糖和半乳糖)在相同条件下衍生化。将反应产物进样到气相色谱(GC),根据样品色谱峰的保留时间和峰面积比例确定样品单糖组成的种类和比例。
小鼠餐后血糖测定方法:
将16只C57BL/6J小鼠分为空白组和实验组,每组8只。小鼠禁食12h,称体重,测量空腹血糖。分别灌胃100μL无菌水和100μL含400mg/kg体重的多糖,15min后,灌胃200μL含1g/kg体重的糊化后的可溶性淀粉溶液(称取1.6g可溶性淀粉于25mL去离子水中,于100℃糊化30min,可溶性淀粉购于国药试剂,货号:9005-84-9),重新计时,并尾尖采血分别测定15min、30min、60min、90min和120min的血糖。
总糖含量测定方法:
首先制备一系列质量浓度的葡萄糖标准液(0.2、0.4、0.6、0.8和1mg/L),再向溶液中加入5%苯酚(1.0mL)和浓硫酸(5mL),置于100℃沸水中反应15min后,冷却至室温,并于490nm波长处测定紫外吸光度值。最后处理数据,制定标准曲线。
样品测定:取1mL多糖溶液按上述步骤操作,测其吸光度值,从而计算其总糖含量。
实施例1:菌株的分离与鉴定
从广西桂林米粉门店采集发酵样品。称取1g样品放入无菌均质袋,加入10mL无菌生理盐水,拍打均质10min。再取均质液进行梯度稀释(101、102、103、104、105和106),各取100μL涂布在培养基平板上,置30℃培养2d。观察菌落生长情况,选取形态不同的菌落作为初筛菌株,接种到发酵培养基中,30℃,200r/min,振荡培养3d。培养液经过12000r/min离心5min,收集菌泥,用于后续菌种鉴定。
以微生物的总DNA作为PCR模板,参照直接PCR试剂盒说明书,采用通用引物27F和1492R进行PCR扩增,PCR扩增条件:95℃5min、94℃30s、55℃30s、72℃90s,循环35次;72℃10min。将PCR扩增产物用琼脂糖电泳检测后送往苏州金唯智生物科技有限公司进行测序,用在NCBI上进行序列比对分析。
经上述方法获得和鉴定的菌株为枯草芽孢杆菌,命名为枯草芽孢杆菌(Bacillussubtilis)STB22,已于2023年4月27日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No.27209。
实施例2:发酵时间优化
(1)将枯草芽孢杆菌STB22于发酵培养基(大豆蛋白胨10g/L、酵母粉4g/L、葡萄糖20g/L、K2HPO4·7H2O 2g/L、醋酸钠5g/L、柠檬酸三铵2g/L、MgSO4·7H2O 0.2g/L、MnSO4·4H2O 0.05g/L)中活化18h,按2%接种量将活化液接种于新鲜的发酵培养基中,于37℃分别发酵24h、48h、72h和96h;
(2)将步骤(1)的发酵液于4℃,10000rpm离心15min获得发酵上清液于沸水中煮沸30min灭酶,冷却至室温;
(3)向步骤(2)灭酶冷却后的溶液中加入15%(v/v)的85%三氯乙酸去除蛋白,10000r/min离心10-20min,除去细胞和蛋白沉淀,得到澄清上清液;
(4)向步骤(3)的上清液中加入3倍体积的无水乙醇,4℃过夜沉淀,10000r/min离心10-20min,得到沉淀。
(5)将步骤(4)的沉淀进行冷冻干燥,即得粉末状的α-淀粉酶抑制剂产品。产物得率(mg/L)=冻干样品质量/发酵体积。
经上述方法获得的产品信息如表1所示,结果表明,产物得率和总糖含量随着发酵时间的延长先增加后降低,可能由于发酵末期部分糖类物质作为菌株的发酵底物。发酵48h的产物得率和总糖含量与发酵72h的相差不大,综合发酵时间和经济考虑,后期选择发酵48h。
表1不同发酵时间获得的枯草芽孢杆菌胞外多糖
实施例3:发酵底物优化
具体实施方式同实施例2,区别在于,将步骤(1)中20g/L葡萄糖碳源用复合碳源代替,复合碳源为5g/L果糖、5g/L甘露糖、5g/L海藻糖和5g/L半乳糖的复合,同时发酵最优时间48h,结果显示产物得率为843mg/L,比仅以葡萄糖为碳源的产物得率高30%。结果表明,碳源的种类可以影响多糖的产量,主要是由于加入的碳源可以促进胞外多糖合成基因的启动并促进相应酶系的合成,从而提高胞外多糖的产量。
实施例4:提取工艺优化
具体实施方式同实施例2,区别在于,将步骤(4)中3倍体积的无水乙醇分别用终浓度为80%、86%、89%和91%的无水乙醇代替。结果显示产物得率分别为650mg/mL、678mg/mL、690mg/mL和706mg/mL,总糖含量分别为58.2%、60.6%、62.4%、65%。结果表明,乙醇浓度可以影响产物得率,乙醇浓度越大,获得的产物得率越高,同时沉淀的产物中糖含量越大。
表2不同乙醇浓度醇沉的枯草芽孢杆菌胞外多糖
实施例5:枯草芽孢杆菌胞外多糖类α-淀粉酶抑制剂的性质与功能表征
由实施例4获得的多糖类α-淀粉酶抑制剂的分子量约为58.91KDa,主要由甘露糖(35.1%)和葡萄糖(58.10%)组成,同时包括半乳糖(5.64%)、木糖(0.24%)、阿拉伯糖(0.22%)和鼠李糖(0.7%)。体外实验结果表明,该抑制剂能有效抑制猪胰腺α-淀粉酶(IC50:0.162mg/mL),且抑制能力强于市售阳性对照阿卡波糖(IC50:0.736mg/mL)(如图1~2所示);同时体内实验结果显示,摄入1g/kg体重的可溶性淀粉之后,小鼠的血糖浓度在餐后15min达到峰值(15.2mmol/L),随后缓慢降低;摄入400mg/kg体重的多糖,小鼠的血糖浓度在餐后30min达到峰值(12.9mmol/L),相比于空白对照的小鼠,其峰值血糖降低15.0%(p<0.05),餐后血糖应答的曲线下方面积(AUC)降低了19.1%(如图5所示),表明该抑制剂能显著降低小鼠的餐后高血糖。
对比例1:
具体实施方式同实施例4,区别在于,用三氯乙酸去除蛋白改为Sevage法去除蛋白并发酵48h,用终浓度为80%的乙醇沉淀,结果显示产物得率为650mg/L,蛋白含量为5.27%,总糖含量为58.2%。相对于85%三氯乙酸去蛋白的方法(蛋白含量7.07%,总糖含量56.4%),采用该方法获得的样品中蛋白含量下降了25.5%,总糖含量下降了3.1%。结果表明,利用Sevage法去除蛋白能够显著降低蛋白含量,但同时也会降低多糖得率。
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (9)
1. 一株枯草芽孢杆菌(Bacillus subtilis)STB22,其特征在于,所述枯草芽孢杆菌STB22于2023年4月27日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC No. 27209。
2.含权利要求1所述枯草芽孢杆菌STB22的微生物制剂。
3. 根据权利要求2所述的微生物制剂,其特征在于,所述微生物制剂中含枯草芽孢杆菌STB22活菌数≥107 CFU/mL。
4.根据权利要求3所述的微生物制剂,其特征在于,所述微生物制剂还含有保护剂;所述保护剂包括但不限于甘油。
5.由权利要求1所述枯草芽孢杆菌STB22制备的α-淀粉酶抑制剂,其特征在于,所述抑制剂含有所述枯草芽孢杆菌STB22发酵生产的多糖。
6.制备权利要求5所述α-淀粉酶抑制剂的方法,其特征在于,包括如下步骤:
(1)将权利要求1所述的枯草芽孢杆菌STB22于培养基中发酵,获得发酵液;
(2)除去步骤(1)所得发酵液中的细胞和蛋白沉淀,得到澄清上清液;
(3)提取步骤(2)所述上清液中的多糖。
7.根据权利要求6所述的方法,其特征在于,步骤(1)所述培养基的碳源为葡萄糖或复合碳源,所述复合碳源包括果糖、甘露糖、海藻糖和半乳糖。
8.根据权利要求6所述的方法,其特征在于,步骤(2)用三氯乙酸法去除蛋白。
9.权利要求1所述的枯草芽孢杆菌STB22,或权利要求2~4任一所述的微生物制剂,或权利要求5所述的α-淀粉酶抑制剂在制备降血糖药品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310830580.6A CN116836872B (zh) | 2023-07-06 | 2023-07-06 | 一种枯草芽孢杆菌多糖类α-淀粉酶抑制剂及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310830580.6A CN116836872B (zh) | 2023-07-06 | 2023-07-06 | 一种枯草芽孢杆菌多糖类α-淀粉酶抑制剂及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116836872A CN116836872A (zh) | 2023-10-03 |
CN116836872B true CN116836872B (zh) | 2023-12-26 |
Family
ID=88168619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310830580.6A Active CN116836872B (zh) | 2023-07-06 | 2023-07-06 | 一种枯草芽孢杆菌多糖类α-淀粉酶抑制剂及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116836872B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101139569A (zh) * | 2007-07-27 | 2008-03-12 | 南开大学 | 一株α-淀粉酶抑制剂生产菌及α-淀粉酶抑制剂的制备方法与应用 |
-
2023
- 2023-07-06 CN CN202310830580.6A patent/CN116836872B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101139569A (zh) * | 2007-07-27 | 2008-03-12 | 南开大学 | 一株α-淀粉酶抑制剂生产菌及α-淀粉酶抑制剂的制备方法与应用 |
Non-Patent Citations (2)
Title |
---|
Cloning and expression of the sucrose phosphorylase gene in Bacillus subtilis and synthesis of kojibiose using the recombinant enzyme;Miaomiao Wang et al.;《Microb Cell Fact》;第1-9页 * |
产β-半乳糖苷酶枯草芽孢杆菌BGJ222培养条件的初步优化;祁艳霞等;《中国饲料》;第25-27页 * |
Also Published As
Publication number | Publication date |
---|---|
CN116836872A (zh) | 2023-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109750070B (zh) | 一种功能性桑叶低聚糖及其制备方法和应用 | |
CN113413351B (zh) | 一种具有美白抗衰功效的发酵液、发酵多肽及其制备方法和应用 | |
CN111317694A (zh) | 一种杜仲发酵提取液及其制备方法和其在化妆品中的应用 | |
CN100368530C (zh) | 一种双歧杆菌胞外多糖及其生产方法与专用生产菌株 | |
CN113564069B (zh) | 一种长双歧杆菌、长双歧杆菌胞外多糖及其提取方法和应用 | |
CN115287240A (zh) | 一株具有高尿酸血症及痛风防治作用的植物乳杆菌及其应用 | |
CN115287239A (zh) | 一株具有体外降解核苷、嘌呤及降尿酸能力的植物乳杆菌及其应用 | |
CN109294944B (zh) | 一种普雷沃肠型体外模拟模型的构建方法 | |
CN113980858A (zh) | 一株产高活性单宁酶的植物乳杆菌yl399及其在制备党参发酵饲料中的应用 | |
CN107012095B (zh) | 猪结肠微生物组体外模拟培养的发酵参数 | |
CN112831444A (zh) | 鼠李糖乳杆菌lr2y及应用 | |
CN116836872B (zh) | 一种枯草芽孢杆菌多糖类α-淀粉酶抑制剂及其应用 | |
CN114196586B (zh) | 一株蒙氏肠球菌及其在发酵中草药中的应用 | |
CN109456898A (zh) | 一种球毛壳菌右旋糖酐酶的发酵制备及其应用 | |
CN113826900A (zh) | 一种结冷胶寡糖及其在益生元中的应用 | |
CN115260324B (zh) | 一种具有肠道益生活性的佛手多糖的制备方法 | |
CN114875104B (zh) | 一种桑叶酵素原液及其制备方法和应用 | |
CN112094751B (zh) | 斜顶菌qyl-10的发酵液及其生产的生物添加剂和应用 | |
CN113372463B (zh) | 一种从蒸馏米酒蒸馏残液中提取益生功能糖的方法 | |
CN114532540B (zh) | 麦芽五糖基海藻糖及其微球在调节肠道菌群中的应用 | |
CN117050923B (zh) | 一株鼠李糖乳杆菌lr06及其在雪绒花发酵中的应用 | |
CN116637141B (zh) | 一种基于微生物发酵得栀子降尿酸代谢产物发酵浸膏的方法 | |
CN117547572B (zh) | 一种组合物的复合乳酸菌发酵品的制备方法、产品及应用 | |
CN115074291B (zh) | 一株能够提高发酵桔梗的活性成分及抗氧化能力的巨大芽孢杆菌、方法和应用 | |
CN112772928B (zh) | 一种发酵腐竹豆清液的制备方法及其在促进肠道健康中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |